Background: The function of this binding protein is not fully known. It is known to interact with the S100P and colocalizes with S100P in the nucleus. S100P may stimulate cell proliferation in an autocrine manner via activation of the receptor for activated glycation end products (RAGE). Expressed in brain, spleen, and lung. Not detected in pancreas or liver. In pancreas, expressed predominantly in islet cells and to a lesser extent in acinar cells, but not expressed in ductal cells. Up-regulated in various pancreatic ductal adenocarcinomas and pancreatic intraepithelial neoplasias. Detected in pancreatic ductal adenocarcinoma cells (at protein level). Not detected in non-neoplastic ductal epithelium (at protein level).
Immunogen: Synthetic peptide derived from human S100P-binding protein.
Purification Method: Antigen Immunoaffiinity Purification
Concentration: See vial for concentration
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
References: 1. Dowen, S.E., et al. ‘Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.’ Am. J. Pathol., 166, 81-92 (2005)2. Deng, H., et al. ‘Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens.’ Am. J. Clin. Pathol., 129, 81-88 (2008)
UniProt: Q96BU1
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
